These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 15010697)

  • 1. Addition of the alpha2-antagonist yohimbine to fluoxetine: effects on rate of antidepressant response.
    Sanacora G; Berman RM; Cappiello A; Oren DA; Kugaya A; Liu N; Gueorguieva R; Fasula D; Charney DS
    Neuropsychopharmacology; 2004 Jun; 29(6):1166-71. PubMed ID: 15010697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized controlled trial of duloxetine versus placebo in the treatment of nonmajor chronic depression.
    Hellerstein DJ; Stewart JW; McGrath PJ; Deliyannides DA; Batchelder ST; Black SR; Withers A; O'Shea D; Chen Y
    J Clin Psychiatry; 2012 Jul; 73(7):984-91. PubMed ID: 22901348
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preliminary randomized double-blind placebo-controlled trial of tryptophan combined with fluoxetine to treat major depressive disorder: antidepressant and hypnotic effects.
    Levitan RD; Shen JH; Jindal R; Driver HS; Kennedy SH; Shapiro CM
    J Psychiatry Neurosci; 2000 Sep; 25(4):337-46. PubMed ID: 11022398
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study.
    Blier P; Ward HE; Tremblay P; Laberge L; Hébert C; Bergeron R
    Am J Psychiatry; 2010 Mar; 167(3):281-8. PubMed ID: 20008946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A double-blind placebo-controlled trial of lamotrigine as an antidepressant augmentation agent in treatment-refractory unipolar depression.
    Barbee JG; Thompson TR; Jamhour NJ; Stewart JW; Conrad EJ; Reimherr FW; Thompson PM; Shelton RC
    J Clin Psychiatry; 2011 Oct; 72(10):1405-12. PubMed ID: 21367355
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fluoxetine once every third day in the treatment of major depressive disorder.
    Tural U; Onder E
    Eur Arch Psychiatry Clin Neurosci; 2003 Dec; 253(6):307-12. PubMed ID: 14714120
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, double-blind, and placebo-controlled trial of quetiapine augmentation of fluoxetine in major depressive disorder.
    Garakani A; Martinez JM; Marcus S; Weaver J; Rickels K; Fava M; Hirschowitz J
    Int Clin Psychopharmacol; 2008 Sep; 23(5):269-75. PubMed ID: 18703936
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications.
    Khin NA; Chen YF; Yang Y; Yang P; Laughren TP
    J Clin Psychiatry; 2011 Apr; 72(4):464-72. PubMed ID: 21527123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Double-blind comparison of bupropion and fluoxetine in depressed outpatients.
    Feighner JP; Gardner EA; Johnston JA; Batey SR; Khayrallah MA; Ascher JA; Lineberry CG
    J Clin Psychiatry; 1991 Aug; 52(8):329-35. PubMed ID: 1907963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of therapeutic effects of omega-3 fatty acid eicosapentaenoic acid and fluoxetine, separately and in combination, in major depressive disorder.
    Jazayeri S; Tehrani-Doost M; Keshavarz SA; Hosseini M; Djazayery A; Amini H; Jalali M; Peet M
    Aust N Z J Psychiatry; 2008 Mar; 42(3):192-8. PubMed ID: 18247193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eszopiclone co-administered with fluoxetine in patients with insomnia coexisting with major depressive disorder.
    Fava M; McCall WV; Krystal A; Wessel T; Rubens R; Caron J; Amato D; Roth T
    Biol Psychiatry; 2006 Jun; 59(11):1052-60. PubMed ID: 16581036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metyrapone as additive treatment in major depression: a double-blind and placebo-controlled trial.
    Jahn H; Schick M; Kiefer F; Kellner M; Yassouridis A; Wiedemann K
    Arch Gen Psychiatry; 2004 Dec; 61(12):1235-44. PubMed ID: 15583115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic effects of vitamin D as adjunctive therapy to fluoxetine in patients with major depressive disorder.
    Khoraminya N; Tehrani-Doost M; Jazayeri S; Hosseini A; Djazayery A
    Aust N Z J Psychiatry; 2013 Mar; 47(3):271-5. PubMed ID: 23093054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study.
    Marcus RN; McQuade RD; Carson WH; Hennicken D; Fava M; Simon JS; Trivedi MH; Thase ME; Berman RM
    J Clin Psychopharmacol; 2008 Apr; 28(2):156-65. PubMed ID: 18344725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The efficacy of fluoxetine combined with a heterocyclic antidepressant in treatment-resistant depression: a retrospective analysis.
    Zajecka JM; Jeffries H; Fawcett J
    J Clin Psychiatry; 1995 Aug; 56(8):338-43. PubMed ID: 7635848
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Switching to reboxetine: an efficacy and safety study in patients with major depressive disorder unresponsive to fluoxetine.
    Fava M; McGrath PJ; Sheu WP;
    J Clin Psychopharmacol; 2003 Aug; 23(4):365-9. PubMed ID: 12920412
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Parallel-group placebo-controlled trial of testosterone gel in men with major depressive disorder displaying an incomplete response to standard antidepressant treatment.
    Pope HG; Amiaz R; Brennan BP; Orr G; Weiser M; Kelly JF; Kanayama G; Siegel A; Hudson JI; Seidman SN
    J Clin Psychopharmacol; 2010 Apr; 30(2):126-34. PubMed ID: 20520285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The vasopressin V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies.
    Griebel G; Beeské S; Stahl SM
    J Clin Psychiatry; 2012 Nov; 73(11):1403-11. PubMed ID: 23146246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
    Zarate CA; Singh JB; Carlson PJ; Brutsche NE; Ameli R; Luckenbaugh DA; Charney DS; Manji HK
    Arch Gen Psychiatry; 2006 Aug; 63(8):856-64. PubMed ID: 16894061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risperidone, an atypical antipsychotic enhances the antidepressant-like effect of venlafaxine or fluoxetine: possible involvement of alpha-2 adrenergic receptors.
    Dhir A; Kulkarni SK
    Neurosci Lett; 2008 Nov; 445(1):83-8. PubMed ID: 18778754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.